Taiwan's Success Story In Combating Covid-19
BioSpectrum Asia|May 2020
COVID-19 has unravelled the potency and the feebleness of most geographical region’s healthcare, technical, social and political structure. While countries are anticipating various dimensions to tackle coronavirus and combat the pandemic, Taiwan’s success in controlling COVID-19 has bolstered its global standing despite the close geographical proximity with China. The resilient island aggregated its forces to tackle the virus and circumstances rationally with well-established pandemic control strategies, bio medical assets, advanced IoT capabilities, impeccable healthcare system and a well organised political force. Taiwan apparently grappled the coronavirus incredibly well and is now keen to offer medical and technical assistance to other countries in this global crisis.
Hithaishi C Bhaskar 
Taiwan's Success Story In Combating Covid-19

Taiwan, an island state in East Asia is located at less than 150 km sea route away from China, the epicentre of COVID-19 outbreak. Among the 23 million population of the island 850 000 reside-in and 404 000 work in China. Though the world’s corona death tool is steeping with elevated graph, Taiwan has recorded only 429 cases and 6 reported deaths as of April 30, 2020.

Taiwan has always been provident from its earlier lessons learnt during SARS outbreak in 2003. Thus, the country became hyper-vigilant once the first case of mysterious pneumonia reported in Wuhan, China. Taiwan developed its proficient and self-established health system to address any upcoming pandemic or epidemic. Taiwan’s advanced hub is combating COVID-19 through science, technology, and democratic proactive governance and most importantly independent of WHO tracking system. Taiwan believes in strategic pre planning prior to the outbreak and constantly reviews immigration policies as and when the situation evolves to monitor any emerging infectious diseases.

Taiwan’ trajectories and execution strategies in assessing COVID-19 and quick actions in preventing a large-scale epidemic may be instructive for other countries as the virus continue to threaten global health and economies.

Rapid response and effective strategies

Ever since the SARS epidemic in 2003, Taiwan has been on constant alert by establishing public health response mechanism which activates emergency public health management structures. Taiwan proficient teams quickly mobilize and institute specific approaches for case identification, containment, and resource allocation.

Bu hikaye BioSpectrum Asia dergisinin May 2020 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

Bu hikaye BioSpectrum Asia dergisinin May 2020 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

BIOSPECTRUM ASIA DERGISINDEN DAHA FAZLA HIKAYETümünü görüntüle
Korea develops micro-structured artificial lung model using bioprinting technology
BioSpectrum Asia

Korea develops micro-structured artificial lung model using bioprinting technology

A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Philips names Ling Liu as Chief Region Leader of Greater China
BioSpectrum Asia

Philips names Ling Liu as Chief Region Leader of Greater China

Royal Philips, a global leader in health technology, has announced the appointment of Ling Liu as the Chief Region Leader of Philips Greater China.

time-read
1 min  |
BioSpectrum Asia Sep 2024
PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals
BioSpectrum Asia

PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals

PW Skills, the upskilling vertical of Physics Wallah (PW) has announced the launch of School of Healthcare across five cities in India, namely, Noida, Indore, Lucknow, Patna and Delhi.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Australian biotech incubator Proto Axiom announces $20 M Series B first close
BioSpectrum Asia

Australian biotech incubator Proto Axiom announces $20 M Series B first close

Proto Axiom, the Australian biomedical technology incubator, has announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology sector through increased intellectual property (IP) retention.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology
BioSpectrum Asia

Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology

Biogen Inc., Beckman Coulter, Inc. (both based in the US) and Japan-based Fujirebio have announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialise new tests for tau pathology in Alzheimer’s disease (AD).

time-read
1 min  |
BioSpectrum Asia Sep 2024
Pfizer upgrades pharma production plant in Melbourne
BioSpectrum Asia

Pfizer upgrades pharma production plant in Melbourne

Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria.

time-read
1 min  |
BioSpectrum Asia Sep 2024
mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines
BioSpectrum Asia

mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines

PlasmidFactory GmbH was founded in 2000 in Bielefeld/Germany with 4 employees. In the meantime, under the founder and managing director Dr. Martin Schleef, the company has become a well-known contract manufacturer (CDMO) for plasmid and minicircle DNA. Today, PlasmidFactory has ~50 highly qualified employees, and has established a GMP manufacturing facility.

time-read
6 dak  |
BioSpectrum Asia Sep 2024
"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"
BioSpectrum Asia

"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"

K Raja Bhanu has been elevated from Executive Director to Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), effective July 1, 2024. Bhanu brings a wealth of experience from his distinguished career in drug control and regulation. He has a proven track record in advancing drug quality, safety, and regulatory compliance. His leadership at the Drug Control Administration (DCA) was marked by significant initiatives that enhanced drug regulation standards and reinforced India's pharmaceutical reputation globally. In his current role, Bhanu is set to drive the expansion of India's pharmaceutical exports, boost global competitiveness, and adeptly navigate the complexities of international regulations, leveraging his extensive expertise to foster industry growth and global prominence. In an interaction with BioSpectrum, he shared his plans on addressing many challenges before the Indian pharma industry to stay compliant with international regulations. Edited excerpts:

time-read
4 dak  |
BioSpectrum Asia Sep 2024
"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"
BioSpectrum Asia

"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"

Australia's first true biotech incubator, Proto Axiom, has secured $20 million in the first close of its $30 million Series B round to strengthen the nation's biotech sector through greater IP retention. Anthony Liveris, CEO of Proto Axio discusses the incubator's selection criteria, identifying the most promising biotech trends for global health, and outlining the key strengths that make Australian biotech globally competitive. Edited excerpts:

time-read
2 dak  |
BioSpectrum Asia Sep 2024
Unleashing Innovative Wound Care Solutions
BioSpectrum Asia

Unleashing Innovative Wound Care Solutions

The incidence of wounds is rising, especially in the Asia-Pacific (APAC) region. In Australia alone, 420,000 individuals are impacted by chronic wounds, leading to direct healthcare costs of AUD $3 billion, representing 2 per cent of the country's total healthcare expenditure. Similarly, data from Singapore between 2000 and 2017 revealed that the incidence of wounds among hospitalised adults was 300 per 100,000 for those over 18 and 800 per 100,000 for those over 50. Let's explore further.

time-read
5 dak  |
BioSpectrum Asia Sep 2024